Evidence map›Paper›PMID 24103211›Full record

Trial reportThe international journal of neuropsychopharmacology2014

Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.

C N Haile, J W Murrough, D V Iosifescu, L C Chang, R K Al Jurdi, A Foulkes, S Iqbal, J J Mahoney, R De La Garza, D S Charney and 2 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The international journal of neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07120477 (Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention), which is not on this map. Cited by 115 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 11 pooled it
17.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07120477 phase4suspendednot on this mapstarted 2026, after this paper: background citation

Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE)

TypeinterventionalSponsorUniversity of Sao PauloRan2026 to 2029Enrolled468ConditionsSuicide Prevention, Ketamine, Crisis Response PlanArmsIntravenous Esketamine, Crisis Response Planning intervention (structures safety planning)
3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 11 syntheses or guidelines pooled it, 248 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression.Journal of child and adolescent psychopharmacology · 2024
    Trial
  13. Trial
  14. Trial
  15. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Trial
  16. Trial
  17. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Trial
  18. Trial
  19. Trial
  20. Trial

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

C N HaileMenninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.
J W MurroughMood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
D V IosifescuMood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
L C ChangDepartment of Anesthesiology, Baylor College of Medicine, New York, NY, USA.
R K Al JurdiMichael E. DeBakey VA Medical Center, Houston, TX, USA.
A FoulkesMenninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.
S IqbalMenninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.
J J MahoneyMenninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.
R De La GarzaMenninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.
D S CharneyMood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
T F NewtonMenninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.
S J MathewMichael E. DeBakey VA Medical Center, Houston, TX, USA.
Baylor College of Medicine · USMichael E. DeBakey VA Medical Center · USIcahn School of Medicine at Mount Sinai · USAllen Institute for Brain Science · US

Funding

Mount Sinai Institutes for Clinical and Translational SciencesUL1TR000067 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SAMPSON, HUGH A · 2012 to 2014
$16.5M
Optimization of IV Ketamine for Treatment Resistant Major DepressionR01MH081870 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MATHEW, SANJAY J · 2009 to 2012
$1.4M
Clinical Research Education for Drug Abuse ProfessionalsR25DA028976 · NIDA · BAYLOR COLLEGE OF MEDICINE · PI NEWTON, THOMAS FREDERICK · 2011 to 2015
$1.2M
Functional MRI Studies of Emotion in Depression and Rapid Antidepressant ResponseK23MH094707 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MURROUGH, JAMES WARREN · 2011 to 2015
$911k
NCATS NIH HHS UL1 TR000067NCATS NIH HHS UL1TR000067NIDA NIH HHS R25 DA028976NIMH NIH HHS 1K23MH094707-01NIMH NIH HHS K23 MH094707NIMH NIH HHS R01 MH081870NIMH NIH HHS R01MH081870
6 · The paper itself

Abstract

Ketamine produces rapid antidepressant effects in treatment-resistant depression (TRD), but the magnitude of response varies considerably between individual patients. Brain-derived neurotrophic factor (BDNF) has been investigated as a biomarker of treatment response in depression and has been implicated in the mechanism of action of ketamine. We evaluated plasma BDNF and associations with symptoms in 22 patients with TRD enrolled in a randomized controlled trial of ketamine compared to an anaesthetic control (midazolam). Ketamine significantly increased plasma BDNF levels in responders compared to non-responders 240 min post-infusion, and Montgomery-Åsberg Depression Rating Scale (MADRS) scores were negatively correlated with BDNF (r=-0.701, p = 0.008). Plasma BDNF levels at 240 min post-infusion were highly negatively associated with MADRS scores at 240 min (r = -0.897, p=.002), 24 h (r = -0.791, p = 0.038), 48 h (r = -0.944, p = 0.001) and 72 h (r = -0.977, p = 0.010). No associations with BDNF were found for patients receiving midazolam. These data support plasma BDNF as a peripheral biomarker relevant to ketamine antidepressant response.

Indexed as

AdultAgedAged, 80 and overBiomarkersBrain-Derived Neurotrophic FactorDepressive Disorder, Treatment-ResistantDouble-Blind MethodFemaleHumansKetamineMaleMidazolamMiddle AgedTreatment OutcomeYoung AdultBDNF protein, humanBiomarkersBrain-Derived Neurotrophic FactorKetamineMidazolam

Identifiers

PMID24103211
PMCPMC3992942
OpenAlexW2167565363

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.